Isavuconazole News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Isavuconazole. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Isavuconazole Today - Breaking & Trending Today

Basilea Pharmaceutica AG: Continued strong Cresemba® (isavuconazole) sales by Pfizer trigger USD 26 million sales milestone payments to Basilea

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, June 08, 2023 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting ....

Basel Stadt , United States , Switzerland General , Mecklenburg Vorpommern , Nils Schr , David Veitch , Stefan Klotter , Asia Pacific , Basilea Pharmaceutica Ltd , European Union , Head Of Corporate Communications Investor Relations , Basilea Pharmaceutica International Ltd , Swiss Exchange , Pharmaceutica Ltd , Chief Executive Officer , Corporate Communications , Pharmaceutica International Ltd , Public Assessment Report , Stabile Ertr , Chart Profi Stefan Klotter , Blue Chips ,

Basilea Pharmaceutica AG: Continued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers second sales milestone payment to Basilea from Pfizer

Basel/Allschwil, Switzerland, February 07, 2023 Basilea Pharmaceutica Ltd. (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial ....

United States , Basel Stadt , Basel Allschwil , Nils Schr , Asia Pacific , Schwierige Zeiten , David Veitch , Head Of Corporate Communications Investor Relations , Swiss Exchange , Basilea Pharmaceutica Ltd , Basilea Pharmaceutica International Ltd , Pfizer Inc , European Union , Chief Executive Officer , Latin America , Middle East , North Africa , Pharmaceutica Ltd , Corporate Communications , Pharmaceutica International Ltd , Public Assessment Report ,

Basilea Pharmaceutica AG: Basilea announces approval for additional formulation of antifungal Cresemba (isavuconazole) in China

Chinese National Medical Products Administration (NMPA) granted Drug Approval License to Basilea's license partner, Pfizer Inc.Intravenous use of Cresemba approved for the treatment of adult patients with ....

United States , Basel Stadt , Basel Allschwil , Nils Schr , David Veitch , Head Of Corporate Communications Investor Relations , Swiss Exchange , Basilea Pharmaceutica Ltd , Basilea Pharmaceutica International Ltd , Pfizer Inc , Chinese National Medical Products Administration , European Union , National Medical Products Administration , Drug Approval License , Latin America , Middle East , North Africa , Pharmaceutica Ltd , Corporate Communications , Pharmaceutica International Ltd , Public Assessment Report ,

Basilea Pharmaceutica AG: Basilea receives USD 10 million milestone payment related to approval of antifungal Cresemba (isavuconazole) in China

Chinese National Medical Products Administration (NMPA) granted Drug Approval License for Cresemba in China to Basilea's license partner Pfizer Ad hoc announcement pursuant to Art. 53 LR Basel ....

United States , Hong Kong , Basel Stadt , Macau General , Nils Schr , David Veitch , Head Of Corporate Communications Investor Relations , Basilea Pharmaceutica Ltd , Swiss Exchange , Pfizer Inc , Chinese National Medical Products Administration , European Union , National Medical Products Administration , Drug Approval License , Drug Evaluation , Asia Pacific , Latin America , Middle East , North Africa , Basilea Pharmaceutica , Corporate Communications , Public Assessment Report ,

Basilea Pharmaceutica AG: Continued strong Cresemba (isavuconazole) sales by Pfizer trigger USD 10 million sales milestone payment to Basilea

Ad hoc announcement pursuant to Art. 53 LR Basel, Switzerland, December 08, 2021 Basilea Pharmaceutica Ltd. (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs ....

United States , Hong Kong , Basel Stadt , Macau General , Nils Schr , David Veitch , Head Of Corporate Communications Investor Relations , European Union , Basilea Pharmaceutica Ltd , Swiss Exchange , Chief Executive Officer , Asia Pacific , Latin America , Middle East , North Africa , Basilea Pharmaceutica , Corporate Communications , Public Assessment Report ,